ROSIGLITAZONE, A REPURPOSED DRUG AS ANTICANCER AGENT: A REVIEW
-
Published:2023-06-30
Issue:
Volume:
Page:303-314
-
ISSN:0974-035X
-
Container-title:Towards Excellence
-
language:en
-
Short-container-title:Towards Excell.
Author:
Patel Binita1, Gelat Brijesh2, SR Kaid Johar2
Affiliation:
1. Department of Life Sciences, School of Sciences, Gujarat University, Ahmedabad 2. Department of Zoology, BMTC, HG and WBC, School of Sciences, Gujarat University, Ahmedabad
Abstract
Different medicinal products can be used to treat various disorders. Finding promising compounds for both established and new illnesses is the goal of drug development. Finding new therapeutic uses for already-approved, withdrawn-from-use, abandoned, and experimental medications is the process of "drug repurposing." Recently, the medication rosiglitazone (ROSI) was used as an anticancer agent. The status and its application as an anticancer agent are described in the current review. In this review, we outlined the function of ROSI as an anticancer agent and covered a variety of ROSI-related topics, including its molecular mechanism of action, anti-angiogenesis properties, function in oxidative stress and inflammation, function in apoptosis and cell cycle, function in cell migration and invasion, and the use of ROSI in combination therapy with other drug agents.
Publisher
Gujarat University
Reference33 articles.
1. Aljada, A., O’Connor, L., Fu, Y. Y., & Mousa, S. A. (2008). PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis, 11(4), 361–367. https://doi.org/10.1007/s10456-008-9118-0 2. Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021). Oxidative stress in cancer cell metabolism. In Antioxidants (Vol. 10, Issue 5, p. 10). https://doi.org/10.3390/antiox10050642 3. Arif, I. S., Hooper, C. L., Greco, F., Williams, A. C., & Boateng, S. Y. (2013). Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. British Journal of Pharmacology, 169(5), 1178–1188. https://doi.org/10.1111/bph.12202 4. Bunt, S. K., Mohr, A. M., Bailey, J. M., Grandgenett, P. M., & Hollingsworth, M. A. (2013). Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunology, Immunotherapy, 62(2), 225–236. https://doi.org/10.1007/s00262-012-1324-3 5. Cao, L. Q., Chen, X. L., Wang, Q., Huang, X. H., Zhen, M. C., Zhang, L. J., Li, W., & Bi, J. (2007). Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacologica Sinica, 28(6), 879–887. https://doi.org/10.1111/j.1745-7254.2007.00571.x
|
|